Efficacy and safety of tarenflurbil, a selective a beta 42-lowering agent, in Alzheimer's disease (AD): A phase 2 trial of up to 24 months of treatment

Samankaltaisia teoksia

• Efficacy and safety of tarenflurbil (flurizan), a selective Abeta42-lowering agent, in Alzheimer's disease (AD): A phase 2 trial of up to 24 months of treatment
  Tekijä: Wilcock, G, et al.
  Julkaistu: (2007)
• Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.
  Tekijä: Wilcock, G, et al.
  Julkaistu: (2008)
• Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial.
  Tekijä: Green, R, et al.
  Julkaistu: (2009)
• Efficacy and safety of MPC-7869 (R-flurbiprofen), a selective ab42-lowering agent, in mild Alzheimer's disease (AD): Results of a 12-month Phase 2 trial and 1-year follow-on study
  Tekijä: Black, S, et al.
  Julkaistu: (2006)
• Flurizan, (MPC-7869, (R)-flurbiprofen) a selective A beta-42 lowering agent in patients with mild to moderate Alzheimer's disease: A randomised, placebo-controlled, double blind trial
  Tekijä: Wilcock, G, et al.
  Julkaistu: (2005)